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Two studies have reported significant associations between susceptibility to prostate cancer and two common
missense variants of the HPC2/ELAC2 gene, with estimated relative risks in the range of two- to threefold. We
investigated whether these polymorphisms could be informative in the prediction of the presence of prostate cancer
in men undergoing prostatic biopsy for the evaluation of an elevated serum-PSA level (4.0 ng/ml). We genotyped
944 men who underwent a prostate biopsy at our institution, as well as a control population of 922 healthy,
unselected women from the same population. The prevalence of the HPC2 Ala541Thr allele was similar in men
with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) ( ).Pp .83
We conclude that HPC2 genotyping is unlikely to be a useful adjunct to PSA in the prediction of the presence of
biopsy-detected prostate cancer in asymptomatic men.
Introduction
Both epidemiological and molecular studies support the
hypothesis that there is a significant hereditary com-
ponent to prostate cancer (MIM 176806) susceptibility
(reviewed by Narod [1998]). Linkage studies of multi-
plex families with prostate cancer have led to the as-
signment of several putative highly penetrant dominant
genes for prostate cancer (Smith et al. 1996; Berthon et
al. 1998; Xu et al. 1998; Gibbs et al. 1999; Berry et al.
2000). In addition, evidence for the contribution of low-
penetrance genes to prostate cancer susceptibility comes
from association studies; many of the candidate genes
are involved in androgen metabolism and include the
gene for the androgen receptor (Giovannucci et al. 1997;
Stanford and Just 1997), SRD5A2 (Makridakis et al.
1999; Jaffe et al. 2000; Nam et al. 2001), and CYP3A4
(MIM 124010) (Rebbeck et al. 1998). The vitamin D
receptor has also been proposed to be a prostate can-
cer–risk modifier (Ingles et al. 1997).
Recently, a gene on chromosome 17p, HPC2/ELAC,
has been mapped and characterized (Tavtigian et al.
2001). HPC2 (MIM 605367) was originally linked to
prostate cancer susceptibility in a large Utah kindred.
The authors of that study proposed that missense var-
iant alleles of HPC2 may function as low-penetrance
modifiers of prostate cancer risk (Tavtigian et al. 2001).
The first variant, Ser217Leu, is located in a hydrophilic
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segment of the protein sequence, and the substitution
of the hydrophobic leucine residue may alter the protein
structure (Tavtigian et al. 2001). A second variant,
Ala541Thr, is adjacent to a histidine motif and may
impair protein function. The two variants are in linkage
disequilibrium, and, to date, all individuals who carry
the Ala541Thr variant have also been found to carry
the Ser217Leu variant. The authors of the study esti-
mated that the Ala541Thr variant was associated with
an odds ratio of 2.4 for prostate cancer ( ). APp .02
second, independent study, of 359 cases and 266 con-
trols, confirmed the original association (Rebbeck et al.
2000).
Men with prostate cancer may present with clinical
manifestations of local or metastatic disease or may be
asymptomatic and come to the attention of physicians
through serum-PSA screening. The incidence of prostate
cancer in North America rose significantly after the in-
troduction of PSA testing. The present study was de-
signed to determine whether the two missense HPC2
variants are associated with an increased risk of screen-
detected prostate cancer among men with an elevated
serum-PSA level. We have genotyped 944 men who had
an elevated serum-PSA level (14.0 ng/ml) and who un-
derwent a prostate biopsy, to establish whether the
HPC2 genotype was predictive of the presence of screen-
detected cancer.
Subjects and Methods
Subjects
Subjects were selected from among all men who had
been consecutively referred, for the evaluation of an el-
evated PSA or abnormal digital rectal examination
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(DRE), to the Prostate Center of the University Health
Network; the men had been referred to the Prostate Cen-
ter by 92 urologists and other physicians in the Toronto
region. In Ontario, there are no formal criteria for PSA
screening, but the practice is widespread. In general,
screening is not recommended to men aged !50 years,
except in the presence of a positive family history. The
study population was not part of a formal screening
program, but it is representative of all clinical referrals.
At the Prostate Center, a transrectal ultrasound–guided
prostate biopsy is recommended if the DRE is abnormal
or if the serum-PSA level is 4.0 ng/ml. Between June
1998 and June 2000, a total of 1,105 men with a PSA
4.0 were asked to participate in the study, of whom
944 (85%) consented. Sextant ultrasound-guided needle
biopsy samples were obtained with an 18-gauge needle
with a spring-loaded biopsy device (Bard Magnum). Ad-
ditional samples were taken from ultrasonically suspect
areas if these areas were outside the sextant distribution.
Of the 944 men who underwent a prostate biopsy, 431
were found to have adenocarcinoma. These men with
invasive cancer served as the cases for the study.
The 513 men who did not show invasive cancer on
the biopsy served as the male controls. These men may
have had prostatic intraepithelial neoplasia (PIN) or be-
nign prostate disease. A second control population con-
sisted of 992 unselected, healthy women who partici-
pated in a study that was designed to identify genetic
determinants of serum-hormone levels. The female con-
trol group was added because women are not at risk for
prostate cancer or related conditions, and the distribu-
tion of HPC2 alleles in women therefore should be rep-
resentative of the underlying population. These women
were aged 17–90 years and were recruited from the Uni-
versity of Toronto, the Bay Centre for Birth Control, the
Health Watch Clinic at Women’s College Hospital in
Toronto, and elsewhere in the Toronto community.
None had had a previous diagnosis of cancer. All women
completed a self-administered questionnaire detailing in-
formation on age, ethnic group, and medical history. In
total, there were 431 cases and 1,505 controls available
for study.
Laboratory Analysis
Genomic DNA was extracted from peripheral blood
through use of Puregene DNA extraction kits. PCRs
were performed using, for each reaction, 25 ng of tem-
plate DNA, 0.4 mM of each primer, 200 mM of each
deoxynucleotide triphosphate, 1.0 mM MgCl2, 2% di-
methyl sulfoxide, 1.25 U of Taq polymerase (Gibco),
and the manufacturer’s standard buffers in a final re-
action volume of 12.5 ml. PCR amplification consisted
of 30 cycles (94C for 1 min, 55C for 1 min, and 72C
for 1 min).
Both of the variants in HPC2 were detected through
use of a procedure modified from that of Tavtigian et al.
(2001). The Ser217Leu variant was detected by TaqI
(New England Biolabs) digestion of a 276-bp PCR frag-
ment amplified by the upstream primer 5′-GTTTTCCCA-
GTCACGACGCATTCCCATGTATGAACGTCT-3′ and
downstream primer 3′-GAAACAGCTATGACCATCTA-
CAAGCATTACAAGGCAGAG-5′. The Ala541Thr var-
iant was identified by Fnu4HI (NEB) digestion of the 419-
bp PCR fragment amplified by the upstream primer
5′-CCAGCCTTTGTGTAAGTCTAC-3′ and the down-
stream primer 3′-AATTCTTGATAGGAAACAGCTAT-
GACCATCAGCTTTGTGGTCCAGCCCAAC-5′. After
digestion, the PCR products were separated on 3% aga-
rose gels and were visualized by UV light after ethidium
bromide staining. For each genotype assay, 25% of the
samples were randomly repeated to ensure consistency in
allele designation.
Data Analysis
We compared the frequencies of the two candidate
polymorphic variants, between the prostate cancer cases
and the controls. The frequencies also were compared
between subgroups defined by age at onset, ethnic group,
family history, and clinical and pathologic findings. Be-
cause serum-PSA levels are not distributed normally, a
log transformation was used when the mean serum-PSA
levels were compared between men with different ge-
notypes. DRE results were categorized as either “nor-
mal” or “abnormal” (asymmetric firmness or a palpable
nodule). Ethnicity was categorized as “white,” “black,”
“Asian,” or “other;” the majority of cases (94%) and
controls (84%) were white. To control for minor dif-
ferences, in ethnic makeup, between cases and controls,
ethnic-subgroup analyses were performed. A family his-
tory of prostate cancer was considered to be positive if
one or more first- or second-degree relatives were re-
ported to have prostate cancer.
Results
A total of 944 men with elevated serum-PSA levels un-
derwent a prostate biopsy. The majority (84.1%) of the
men were white; 9.1% were black, 5.5% were Asian
and 1.3% were of other ethnic backgrounds. The mean
serum-PSA level was 12.8 ng/ml (range 4.0–499 ng/ml).
The mean age at biopsy was 65.6 years (range 42–91
years). Fifteen percent of the cases had a positive family
history of prostate cancer (mean age 64.2 years).
Twenty-seven percent of the subjects had a previous bi-
opsy that did not show evidence of cancer.
Of the 944 men examined, 431 (45.7%) were found
to have adenocarcinoma of the prostate (the case
group). The remainder of the men (513 [54.3%]) had
no evidence of invasive cancer (the control group); of
these, 33 had normal prostate tissue, 356 had benign
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Table 1
Comparison of Patients with Prostate Cancer and Male
Controls
SUBGROUP
NO. (PROPORTION OF
TOTAL SAMPLE) IN
P
VALUEaCases Controls
Age (years):b
!51 8 (1.9%) 18 (3.5%)
51-60 96 (22.3%) 130 (25.3%)
61-70 174 (40.3%) 243 (47.4%)
170 153 (35.5%) 122 (23.8%) .0007
Ethnic group:
White 379 (87.9%) 415 (80.9%)
Black 37 (8.6%) 49 (9.6%)
Asian 10 (2.3%) 2 (8.2%)
Other 5 (1.2%) 7 (1.4%) .001
Serum-PSA levelc
(ng/ml):
4 – 9.9 248 (57.5%) 337 (65.7%)
10 – 19.9 126 (29.2%) 144 (28.1%)
20 57 (13.2%) 32 (6.2%) .0006
DRE:
Normal 206 (48.5%) 367 (72.5%)
Abnormal 219 (51.5%) 139 (27.5%) !.0001
Family history:
Positive 57 (16.5%) 59 (13.6%)
Negative 286 (83.4%) 375 (86.4%) .24
a Calculated, for the comparison of proportions, by the x2
statistic.
b Mean age of cases p 66.0 years; mean age of controls
p 63.9 years (P value [Student’s t-test] p .0001).
c Mean in cases p 16.0 ng/ml; mean in controls p 10.1
ng/ml (P value [Student’s t-test] p .0007). Median in cases
p 8.8 ng/ml; median in controls p 8.2 ng/ml.
Table 2
Genotypes of HPC2 Polymorphisms in Cases and Controls
POLYMORPHISM
NO. (PROPORTION OF TOTAL SAMPLE) IN
Cases
Controls
Male Controls Female Controls
Ser217Leu:
Ser/Ser 220 (51.0%) 259 (50.5%) 522 (52.6%)
Ser/Leu 169 (39.2%) 213 (41.5%) 374 (37.7%)
Leu/Leu 42 (9.8%) 41 (8.0%) 96 (9.7%)
Ala541Thr:
Ala/Ala 404 (93.8%) 478 (93.2%) 930 (93.8%)
Ala/Thr 26 (6.0%) 34 (6.6%) 61 (6.1%)
Thr/Thr 1 (.2%) 1 (.2%) 1 (.1%)
findings (inflammation, benign prostatic hyperplasia, or
cellular atypia), and 124 had PIN. Cases and controls
are compared in table 1. The cases were, on average, 2
years older than the controls, were more likely to have
had an abnormal DRE, and had a higher mean serum-
PSA level. These are established risk factors for prostate
cancer. With the exception of Asians, the distributions
of ethnic subgroups within the case and control groups
were similar.
The Ser217Leu missense variant was present in
49.0% of the cases, in 49.5% of the male controls, and
in 47.4% of the female controls ( ) (table 2).Pp .86
There was no significant difference, in the prevalence
of this variant, between the two control groups. The
probabilities of prostate cancer detection were 45.9%
for men with no variant allele, 44.2% for men with one
variant allele, and 50.6% for men with two variant
alleles ( ).Pp .57
The Ala541Thr variant was present in 6.3% of the
cases, 6.8% of the male controls, and 6.3% of the fe-
male controls ( ) (table 2). The probabilities ofPp .83
prostate cancer detection were 45.8% in men with no
variant allele, 43.3% in men with one variant allele,
and 50.0% in men with two variant alleles ( ).Pp .93
The two variants were in Hardy-Weinberg equilibrium
in the case group and in both control groups. The two
missense variants are in linkage disequilibrium, and all
carriers of the Ala541Thr variant also carried the
Ser217Leu variant. Only 12 cases (2.8%) were homo-
zygous for both the Ala541Thr variant and the
Ser217Leu variant. This frequency was slightly greater
than the frequency of double homozygotes in the male
controls (1.9%) and in the female controls (1.9%), but
the difference was not statistically significant (Pp
)..18
Asians constituted a smaller proportion of the case
group than of the control group (2.5% and 8.2%, re-
spectively; ); this difference reflects the rela-P ! .001
tively low prevalence of prostate cancer among Asians
in Ontario. To control for possible confounding due to
ethnic group, the data were analyzed in terms of ethnic
subgroup (table 3). Among whites, the Ser217Leu var-
iant was present in 52.0% of the cases and in 52.4%
of the controls. Ser217 homozygotes constituted 10.3%
of the cases and 9.9% of the controls. There were no
significant associations among the subgroups of black
and Asian men. The Ala541Thr variant was not ob-
served in black or Asian men (table 3); therefore, it was
only possible to evaluate the association in the white
subgroup of cases and controls. Among whites, the
Ala541Thr variant was present in 7.1% of cases and in
7.2% of controls ( ).Pp .90
It has been reported elsewhere that the association
between prostate cancer and the Ala541Thr variant is
modified by age at diagnosis (Tavtigian et al. 2001). In
the present study, no effect was seen in any subgroup
defined by year of birth (table 4).
There was no significant association between the pres-
ence of the HPC2 Ala541Thr variant and the results of
the DRE. Among cases, 5.8% of men with a normal
DRE carried the variant, compared with 6.8% of men
with an abnormal DRE ( ); among controls,Pp .67
7.9% of men with a normal DRE carried the variant,
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Table 3
Prevalence of HPC2 Variant Alleles, by Ethnic Group in Cases and Controls
POLYMORPHISM
AND ETHNIC GROUP
NO. (PROPORTION OF TOTAL SAMPLE) IN
Cases
Controls
Males Females Combined
Ser217Leu:
White 197 (52.0%) 227 (54.7%) 380 (51.1%) 607 (52.4%)
Black 11 (29.7%) 18 (36.7%) 32 (38.6%) 50 (37.9%)
Asian 2 (20.0%) 5 (11.9%) 11 (13.1%) 16 (12.1%)
Other 1 (20.0%) 4 (57.1%) 47 (57.3%) 51 (57.3%)
Ala541Thr:
White 27 (7.1%) 34 (8.2%) 49 (6.6%) 83 (7.2%)
Black 0 0 0 0
Asian 0 0 4 (4.8%) 4 (3.2%)
Other 0 1 (14.3%) 9 (11.0%) 10 (11.2%)
Table 4
Prevalence of HPC2 Variant Alleles, by Year of Birth (Cases
Only)
Polymorphism and
Year of Birth No. (Proportion of Total Sample)
Ser217Leu:
1900–1920 ( )np 26 14 (53.9%)
1920–1930 ( )np 127 58 (45.7%)
1930–1940 ( )np 174 86 (49.4%)
1940– ( )np 104 53 (51.0%)
Ala541Thr:
1900–1920 ( )np 26 2 (7.8%)
1920–1930 ( )np 127 8 (6.3%)
1930–1940 ( )np 174 10 (5.8%)
1940– ( )np 104 7 (6.7%)
compared with 4.3% of men with an abnormal DRE
( ).Pp .16
Because the male subjects were selected for a serum-
PSA level 14.0 ng/ml, the prevalence of benign and pre-
neoplastic prostate disease in this population was high.
However, the frequency of the Ala541Thr variant was
similar for all subgroups with pathologies (table 5).
There was a nonsignificant association between the
presence of the Ala541Thr variant allele and tumor
grade. The variant was present in 9.8% of 122 men
with low-grade tumors (Gleason grades 2–6), in 5.0%
of 221 men with intermediate-grade tumors (Gleason
7), and in 4.9% of 82 men with high-grade tumors
(Gleason 8–10) ( ).Pp .18
The HPC2 gene was initially identified through the
study of familial cases of prostate cancer (Tavtigian et
al. 2001). In the present study, there was a modest as-
sociation between the presence of the Ala541Thr var-
iant and a family history of prostate cancer. Among
cases, the variant was present in 2 (3.5%) of 57 familial
cases and in 20 (7.0%) of 286 non-familial cases
( ); among controls, the variant was present inPp .33
8 (13.6%) of 59 men with a family history of prostate
cancer, compared with 20 (5.3%) of 375 men without
a family history ( ).Pp .04
A borderline-significant association was present be-
tween the mean serum-PSA level at diagnosis and the
HPC2 genotype. Among cases, the (geometric) mean
serum-PSA level was 8.3 ng/ml for carriers of one or
two Ala541Thr alleles and was 10.7 ng/ml for noncar-
riers (t-test on log-transformed serum-PSA level; Pp
). The frequency of the Ala541Thr allele was 7.7%.07
among cases with a serum-PSA level of 4.0–9.9 ng/ml,
4.8% among cases with a serum-PSA level of 10.0–19.9
ng/ml, and 3.5% among cases with a serum-PSA level
of 20.0 ng/ml ( ). Among controls, the meanPp .36
serum-PSA level was 10.1 ng/ml for carriers of the
Ala541Thr allele and was 10.0 ng/ml for noncarriers
( ).Pp .54
Discussion
Our data do not support the hypothesis that common
missense variants of the HPC2 gene predict prostate can-
cer risk among men with an elevated serum-PSA level.
We observed the same frequencies of the Ser217Leu var-
iant and of the Ala541Thr variant in 431 men with
screen-detected cancer and in 513 men with negative
prostate biopsies. Furthermore, the frequency (6.6%) of
the Ala541Thr variant in our population of 944 men
who were referred for prostate biopsy because of a high
serum-PSA level was not substantially different from the
frequency (6.3%) in a group of 992 control women un-
affected with cancer.
There are several possible reasons why we did not see
an association between the Ala541Thr variant and the
risk of screen-detected prostate cancer. Our CI for the
odds ratio was relatively wide (odds ratio .97; 95% CI
0.58–1.63), and our data are consistent with the pos-
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Table 5
Prevalence of HPC2 Variant Alleles, by Prostate Pathology
Polymorphism and
Prostate Pathology
No. (Proportion
of Total Sample)
Ser217Leu:
Cancer ( )np 431 211 (49.0%)
Hyperplasia or inflammation ( )np 356 180 (50.6%)
PIN ( )np 124 60 (48.4%)
Normal ( )np 33 14 (42.4%)
Ala541Thr:
Cancer ( )np 431 27 (6.3%)
Hyperplasia or inflammation ( )np 356 24 (6.7%)
PIN ( )np 124 9 (7.3%)
Normal ( )np 33 2 (6.1%)
sibility that a modest relative risk is associated with the
missense allele. There were important differences in the
selection of cases for the present study and for the two
studies by other researchers (discussed below), but it
appears that the principal reason for the different results
is variation in the control frequencies. We observed the
Ala541Thr variant in 6.3% of cases and in 6.4% of
controls, compared with 9.8% of cases and 3.4% of
controls in the study by Tavtigian et al. (2001) and 7.5%
of cases and 3.5% of controls in the study by Rebbeck
et al. (2000). The size of the control group (1,505 in-
dividuals) in the present study was much larger than
the total (406 individuals) in the two previous studies
combined. The extent to which ethnic variation between
the study populations accounts for the differences in the
allele frequencies reported is not clear. Future studies
will help to establish whether the frequency of the var-
iant genotypes in the previous two studies has been
underestimated.
It is possible that differences in the ethnic makeup of
the cases and controls will lead to a spurious effect in
an association study. We did not observe the Ala541Thr
variant in the nonwhite cases or in nonwhite male con-
trols. However, when the analysis was restricted to
white subjects, no association was present (odds ratio
1.1; 95% CI 0.48–2.5; ).Pp .84
A second limitation of our study is that a single pros-
tate biopsy was performed. Among patients with ele-
vated serum-PSA levels, false-negative biopsies are com-
mon (Fleshner et al. 1997). On rebiopsy, up to 30% of
these patients are found to have cancer, and, therefore,
we may have considerable misclassification in our study.
However, because we found no significant difference, in
the frequencies of the two candidate alleles, between the
men with screen-detected cancer and healthy female
controls, misclassification cannot account entirely for
our negative findings.
Rebbeck et al. (2000) studied incident cases of prostate
cancer, including men who presented with clinical dis-
ease. Our study population was restricted to incident
cases of screen-detected prostate cancer, and all of our
(male) controls had elevated serum-PSA levels. It is pos-
sible that genetic predisposing factors for the two clinical
subgroups are different. It is also possible that the
Ala541Thr variant may be associated with a serum
PSA–level increase that is independent of the presence of
prostate cancer—and that this increase in the serum-PSA
level may prompt a diagnostic evaluation. In asymp-
tomatic men, an increasing proportion of prostate cancer
cases are diagnosed as a result of the PSA-screening test,
and the prevalence of prostate cancer among screened
men in the general population is ∼4% (Narod et al.
1995). Therefore, any gene that leads to an increase in
serum-PSA level may appear to be a prostate can-
cer–susceptibility gene if nonscreened controls are used
in an association study. Becausemean PSAvalues increase
with age, this may also explain the observation, in the
study by Tavtigian et al. (2001), that the frequency of
the Ala541Thr allele increases with age. However, we
observed a modestly lower mean serum-PSA level among
cases with the Ala541Thr variant, compared with the
level among cases without this allele. No difference was
seen in the control group. Furthermore, no overall excess
of the Ala541Thr genotype was seen in the male control
group (selected for elevated PSA) compared with the fe-
male control group. We saw a marginally significant as-
sociation between the presence of the Ala54Thr variant
and a family history of prostate cancer in the controls,
but this was not seen among the cases. In conclusion,
our data do not support the hypothesis that variant mis-
sense alleles of the HPC2 gene influence prostate cancer
susceptibility.
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